Top

Published in:

Open Access 01-06-2012 | Epidemiology

Prevalence of BRCA1 and BRCA2 mutations in non-familial breast cancer patients with high risks in Korea: The Korean Hereditary Breast Cancer (KOHBRA) Study

Authors: Byung Ho Son, Sei Hyun Ahn, Sung-Won Kim, Eunyoung Kang, Sue K. Park, Min Hyuk Lee, Woo-Chul Noh, Lee Su Kim, Yongsik Jung, Ku Sang Kim, Dong-Young Noh, Byung-In Moon, Young Jin Suh, Jeong Eon Lee, Doo Ho Choi, Sung Yong Kim, Sung Hoo Jung, Cha Kyong Yom, Hyde Lee, Jung-Hyun Yang, the KOHBRA Research Group and the Korean Breast Cancer Society

Published in: Breast Cancer Research and Treatment | Issue 3/2012

Abstract

Prevalence and phenotype of BRCA mutation can vary by race. The purpose of this study is to evaluate the prevalence of BRCA1/2 mutations in non-familial breast cancer patients with high risks in Korea. A subset of 758 patients was selected for this study from the KOHBRA nationwide multicenter prospective cohort study. Mutations in BRCA1/2 genes were tested using fluorescent-conformation sensitive gel electrophoresis, denaturing high performance liquid chromatography or direct sequencing. Mutation of BRCA1/2 genes were identified in 65 (8.6%) patients among total 758 patients [BRCA1 mutation: 25 (3.3%), BRCA2 mutation: 40 (5.3%)]. According to risk groups, mutation of BRCA1/2 genes were identified in 53 (8.5%) of 625 early onset patients (age ≤40), in 22 (17.7%) of 124 bilateral breast cancer patients, in 3 (50.0%) of 6 breast and ovarian cancer patients, in one (5.9%) of 17 male breast cancer patients, in 5 cases (7.6%) of 66 multiple organ cancer patients. The most common mutation was 509C>A for BRCA1 and 7708C>T for BRCA2. The prevalence of BRCA1/2 mutations by age in early onset patients was significantly different (age <35 vs age ≥35; 10.0 vs 2.9%, p = 0.0007). BRCA1/2 mutations for non-familial Korean breast cancer patients were detected at a high rate, particularly, in patients with early onset of less than 35 years of age, bilateral breast cancer, and breast and ovarian cancer. Individualized genetic counseling should be offered for non-familial breast cancer patients with these risk factors.

Schwartz GF, Hughes KS, Lynch HT et al (2008) Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. Cancer 113:2627–2637PubMedCrossRef

Brose MS, Rebbeck TR, Calzone KA et al (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94:1365–1372PubMedCrossRef

Easton DF, Bishop DT, Ford D et al (1993) Genetic linkage analysis in familial breast and ovarian cancer: result from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 52:678–701PubMed

King MC, Marks JH, Mandel JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643–646PubMedCrossRef

Honrado E, Osorio A, Palacios J et al (2006) Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations. Oncogene 25:5837–5845PubMedCrossRef

Foulkes WD, Stefansson IM, Chappuis PO et al (2003) Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95:1482–1485PubMedCrossRef

Liede A, Karlan BY, Narod SA (2004) Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 22:735–742PubMedCrossRef

Robson ME (2007) Treatment of hereditary breast cancer. Semin Oncol 34:384–391PubMedCrossRef

Wainberg S, Husted J (2004) Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation. Cancer Epidemiol Biomarkers Prev 13:1989–1995PubMed

10.

Narod SA, Offit K (2005) Prevention and management of hereditary breast cancer. J Clin Oncol 23:1656–1663PubMedCrossRef

11.

Clinical Practice Guidelines in Oncology (2010) Genetic/familial high risk assessment: breast and ovarian cancer. 2010. National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/PDF/genetics_screening.pdf. Accessed 20 Dec 2010

12.

Balmaña J, Diez O, Rubio I et al (2010) BRCA in breast cancer: ESMO Clinical Practice Guidelines. Ann Oncol 21(supple):v20–v22PubMedCrossRef

13.

Lee JA, Kim KI, Bae JW et al (2010) Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival. Breast Cancer Res Treat 123:177–187PubMedCrossRef

14.

Chlebowski RT, Chen Z, Anderson GL et al (2005) Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst 97:439–448PubMedCrossRef

15.

Son BH, Kwak BS, Kim JK et al (2006) Changing patterns in the clinical characteristics of Korean patients with breast cancer during the last 15 years. Arch Surg 141:155–160PubMedCrossRef

16.

Ahn SH, Yoo KY, The Korean Breast Cancer Society (2006) Chronological changes of clinical characteristics in 31,115 new breast cancer patients among Koreans during 1996–2004. Breast Cancer Res Treat 99:209–214PubMedCrossRef

17.

American Cancer Society (2009) Breast Cancer Facts and Figures 2009–2010. American Cancer Society, Inc., Atlanta

18.

Weitzel JN, Lagos VI, Gullinane CA et al (2007) Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA 297:2587–2595PubMedCrossRef

19.

Nagy R, Sweet K, Eng C (2004) Highly penetrant hereditary cancer syndromes. Oncogene 23:6445–6470PubMedCrossRef

20.

Liede A, Narod SA (2002) Hereditary breast and ovarian cancer in Asia: genetic epidemiology of BRCA1 and BRCA2. Hum Mutat 20:413–424PubMedCrossRef

21.

Neuhausen SL (2000) Founder populations and their uses for breast cancer genetics. Breast Cancer Res 2:77–81PubMedCrossRef

22.

Oh JH, Noh DY, Choe KJ et al (1995) Germline mutation of BRCA1 gene in Korean breast and ovarian cancer patients. J Korean Cancer Assoc 27:1061–1069

23.

Kang HC, Kim IJ, Park JH et al (2002) Germline mutations of BRCA1 and BRCA2 in Korean breast and/or ovarian cancer families. Hum Mutat 20:235–239PubMedCrossRef

24.

Choi DH, Lee MH, Bale AE et al (2004) Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients. J Clin Oncol 22:1638–1645PubMedCrossRef

25.

Seo JH, Cho DY, Ahn SH et al (2004) BRCA1 and BRCA2 germline mutations in Korean patients with sporadic breast cancer. Hum Mutat 24:350PubMedCrossRef

26.

Ahn SH, Hwang UK, Kwak BS et al (2004) Prevalence of BRCA1 and BRCA2 Mutations in Korean Breast Cancer Patients. J Korean Med Sci 19:269–274PubMedCrossRef

27.

Ahn SH, Son BH, Yoon KS et al (2007) BRCA1 and BRCA2 germline mutations in Korean breast cancer patients at high risk of carrying mutations. Cancer Lett 8(245):90–95CrossRef

28.

Han SH, Lee KR, Lee DG et al (2006) Mutation analysis of BRCA1 and BRCA2 from 793 Korean patients with sporadic breast cancer. Clin Genet 70:496–501PubMedCrossRef

29.

Kim BY, Lee DG, Lee KR et al (2006) Identification of BRCA1 and BRCA2 mutations from Korean breast cancer patients using denaturing HPLC. Biochem Biophys Res Commun 349:604–610PubMedCrossRef

30.

Kim TJ, Lee KM, Choi CH et al (2006) Germline mutations of BRCA1 in two Korean hereditary breast/ovarian cancer families. Oncol Rep 15:565–569PubMed

31.

Kim EK, Kim KS, Park SK et al (2007) The Korean Hereditary Breast Cancer (KOHBRA) Study: protocol review. J Breast Cancer 10:241–247CrossRef

32.

Han SA, Park SK, Ahn SH et al (2011) The Korean Hereditary Breast Cancer (KOHBRA) Study: protocols and report. Clin Oncol (R Coll Radiol) 23(7):434–441CrossRef

33.

U.S. Preventive Services Task Force (2005) Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 5:355–361

34.

Kurian AW (2010) BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications. Curr Opin Obstet Gynecol 22:72–78PubMedCrossRef

35.

John EM, Miron A, Gong G et al (2007) Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA 298:2869–2876PubMedCrossRef

36.

Gershoni-Baruch R, Dagan E, Fried G et al (1999) BRCA1 and BRCA2 founder mutations in patients with bilateral breast cancer. Eur J Hum Genet 7:833–836PubMedCrossRef

37.

Rogozińska-Szczepka J, Utracka-Hutka B, Grzybowska E et al (2004) BRCA1 and BRCA2 mutations as prognostic factors in bilateral breast cancer patients. Ann Oncol 15:1373–1376PubMedCrossRef

38.

Basham VM, Lipscombe JM, Ward JM et al (2002) BRCA1 and BRCA2 mutations in a population based study of male breast cancer. Breast Cancer Res 4:1–5CrossRef

39.

Couch FJ, Farid LM, Deshano ML et al (1996) BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 13:123–125PubMedCrossRef

40.

Friedman LS, Gayther SA, Kurosaki T et al (1997) Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 60:313–319PubMed

41.

Mavraki E, Gray IC, Bishop T et al (1997) Germline BRCA2 mutations in men with breast cancer. Br J Cancer 76:1428–1431PubMedCrossRef

42.

Haraldsson K, Loman N, Zhang OX et al (1998) BRCA2 germline mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Res 58:1367–1371PubMed

43.

Csokay B, Udvarhelyi N, Sulyok Z et al (1999) High frequency of germline BRCA2 mutations among Hungarian male breast cancer patients without a family history. Cancer Res 59:995–998PubMed

44.

Ding YC, Steele L, Kuan CJ et al (2011) Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States. Breast Cancer Res Treat 126:771–778PubMedCrossRef

45.

Kim YT, Nam EJ, Yoon BS et al (2005) Germline mutations of BRCA1 and BRCA2 in Korean sporadic ovarian carcinoma. Gynecol Oncol 99:585–590PubMedCrossRef

46.

Frank TS, Deffenbaugh AM, Reid JE et al (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 20:1480–1490PubMedCrossRef

Title: Prevalence of BRCA1 and BRCA2 mutations in non-familial breast cancer patients with high risks in Korea: The Korean Hereditary Breast Cancer (KOHBRA) Study
Authors: Byung Ho Son
Sei Hyun Ahn
Sung-Won Kim
Eunyoung Kang
Sue K. Park
Min Hyuk Lee
Woo-Chul Noh
Lee Su Kim
Yongsik Jung
Ku Sang Kim
Dong-Young Noh
Byung-In Moon
Young Jin Suh
Jeong Eon Lee
Doo Ho Choi
Sung Yong Kim
Sung Hoo Jung
Cha Kyong Yom
Hyde Lee
Jung-Hyun Yang
the KOHBRA Research Group and the Korean Breast Cancer Society
Publication date: 01-06-2012
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-012-2001-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2012

Vitamin D threshold to prevent aromatase inhibitor-related bone loss: the B-ABLE prospective cohort study

Rare germline large rearrangements in the BRCA1/2 genes and eight candidate genes in 472 patients with breast cancer predisposition

Triggering of Toll-like receptor 4 on metastatic breast cancer cells promotes αvβ3-mediated adhesion and invasive migration

GPER mediates the Egr-1 expression induced by 17β-estradiol and 4-hydroxitamoxifen in breast and endometrial cancer cells

Associated expressions of FGFR-2 and FGFR-3: from mouse mammary gland physiology to human breast cancer

Beyond taxanes: the next generation of microtubule-targeting agents

Keynote webinar | Spotlight on antibody–drug conjugates in cancer